Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$49.31 USD
+0.22 (0.45%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $49.78 +0.47 (0.95%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Rhythm Pharmaceuticals, Inc. (RYTM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$57.50 | $79.00 | $48.00 | 17.13% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Rhythm Pharmaceuticals, Inc. comes to $57.50. The forecasts range from a low of $48.00 to a high of $79.00. The average price target represents an increase of 17.13% from the last closing price of $49.09.
Analyst Price Targets (8 )
Broker Rating
Rhythm Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.38 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on nine recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 12.5% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RYTM.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.38 | 1.38 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
7/25/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
6/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/8/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
1/25/2024 | Goldman Sachs | Corinne Johnson | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.38 |
ABR (Last week) | 1.38 |
# of Recs in ABR | 8 |
Average Target Price | $57.50 |
LT Growth Rate | 19.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 253 |
Current Quarter EPS Est: | -0.81 |
RYTM FAQs
Rhythm Pharmaceuticals, Inc. (RYTM) currently has an average brokerage recommendation (ABR) of 1.38 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 8 brokerage firms.
The average price target for Rhythm Pharmaceuticals, Inc. (RYTM) is $57.50. The current on short-term price targets is based on 7 reports.
The forecasts for Rhythm Pharmaceuticals, Inc. (RYTM) range from a low of $48 to a high of $79. The average price target represents a increase of $17.13 from the last closing price of $49.09.
The current UPSIDE for Rhythm Pharmaceuticals, Inc. (RYTM) is 17.13%
Based on short-term price targets offered by eight analysts, the average price target for Rhythm Pharmaceuticals, Inc. comes to $57.50. The forecasts range from a low of $48.00 to a high of $79.00. The average price target represents an increase of 17.13% from the last closing price of $49.09.